226 related articles for article (PubMed ID: 17662185)
1. [Positron emission tomography with 18F-fluorodeoxyglucose in patients with uterine sarcoma].
Rebollo Aguirre AC; Ramos Font C; Bellón Guardia ME; Cabello García D; Gallego Peinado M; Rodríguez Fernández A; Llamas Elvira JM
Rev Esp Med Nucl; 2007; 26(4):189-95. PubMed ID: 17662185
[TBL] [Abstract][Full Text] [Related]
2. Whole-body positron emission tomography with F-18 fluorodeoxyglucose for the detection of recurrence in uterine sarcomas.
Murakami M; Tsukada H; Shida M; Watanabe M; Maeda H; Koido S; Hirasawa T; Muramatsu T; Miyamoto T; Nasu S; Yasuda S; Kajiwara H; Yasuda M; Ide M
Int J Gynecol Cancer; 2006; 16(2):854-60. PubMed ID: 16681773
[TBL] [Abstract][Full Text] [Related]
3. Positron emission tomography with (18)F-fluorodeoxyglucose of uterine sarcoma: a comparison with magnetic resonance imaging and power Doppler imaging.
Umesaki N; Tanaka T; Miyama M; Kawamura N; Ogita S; Kawabe J; Okamura T; Koyama K; Ochi H
Gynecol Oncol; 2001 Mar; 80(3):372-7. PubMed ID: 11263934
[TBL] [Abstract][Full Text] [Related]
4. Role of FDG PET-CT in detecting recurrence in patients with uterine sarcoma: comparison with conventional imaging.
Sharma P; Kumar R; Singh H; Jeph S; Sharma JB; Jain SK; Sharma DN; Bal C; Malhotra A
Nucl Med Commun; 2012 Feb; 33(2):185-90. PubMed ID: 22107993
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic performance of fluorine-18-fluorodeoxyglucose positron emission tomography imaging in uterine sarcomas: systematic review and meta-analysis of the literature.
Sadeghi R; Zakavi SR; Hasanzadeh M; Treglia G; Giovanella L; Kadkhodayan S
Int J Gynecol Cancer; 2013 Oct; 23(8):1349-56. PubMed ID: 23945203
[TBL] [Abstract][Full Text] [Related]
6. Value of 18F-FDG PET/CT imaging in the staging, restaging, monitoring of response to therapy and surveillance of uterine leiomyosarcomas.
Bélissant O; Champion L; Thevenet H; Weinmann P; Alberini JL
Nucl Med Commun; 2018 Jul; 39(7):652-658. PubMed ID: 29683931
[TBL] [Abstract][Full Text] [Related]
7. Imaging of gynecologic tumors: comparison of (11)C-choline PET with (18)F-FDG PET.
Torizuka T; Kanno T; Futatsubashi M; Okada H; Yoshikawa E; Nakamura F; Takekuma M; Maeda M; Ouchi Y
J Nucl Med; 2003 Jul; 44(7):1051-6. PubMed ID: 12843219
[TBL] [Abstract][Full Text] [Related]
8. Whole-body positron emission tomography with 18F-fluorodeoxyglucose is an effective method to detect extra-pelvic recurrence in uterine sarcomas.
Sung PL; Chen YJ; Liu RS; Shieh HJ; Wang PH; Yen MS; Wen KC; Shen SH; Lai CR; Yuan CC
Eur J Gynaecol Oncol; 2008; 29(3):246-51. PubMed ID: 18592788
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of preoperative ¹⁸F-FDG PET/CT in uterine leiomyosarcoma.
Park JY; Lee JW; Lee HJ; Lee JJ; Moon SH; Kang SY; Cheon GJ; Chung HH
J Gynecol Oncol; 2017 May; 28(3):e28. PubMed ID: 28382795
[TBL] [Abstract][Full Text] [Related]
10. Clinical use of combined positron emission tomography and computed tomography (FDG-PET/CT) in recurrent ovarian cancer.
Thrall MM; DeLoia JA; Gallion H; Avril N
Gynecol Oncol; 2007 Apr; 105(1):17-22. PubMed ID: 17208284
[TBL] [Abstract][Full Text] [Related]
11. F-18 fluorodeoxyglucose positron-emission tomography in the diagnosis of tumor recurrence and metastases in the follow-up of patients with breast carcinoma: a comparison to conventional imaging.
Gallowitsch HJ; Kresnik E; Gasser J; Kumnig G; Igerc I; Mikosch P; Lind P
Invest Radiol; 2003 May; 38(5):250-6. PubMed ID: 12750613
[TBL] [Abstract][Full Text] [Related]
12. Positron emission tomography/computed tomography with 18fluoro-deoxyglucose in the detection of local recurrence and distant metastases of pediatric sarcoma.
Arush MW; Israel O; Postovsky S; Militianu D; Meller I; Zaidman I; Sapir AE; Bar-Shalom R
Pediatr Blood Cancer; 2007 Dec; 49(7):901-5. PubMed ID: 17252575
[TBL] [Abstract][Full Text] [Related]
13. Fluorine-18-fluorodeoxyglucose PET/CT for the evaluation of suspected recurrent uterine leiomyosarcomas.
Kao YH; Saad U; Tan AE; Magsombol BM; Padhy AK
Acta Radiol; 2011 May; 52(4):463-6. PubMed ID: 21498277
[TBL] [Abstract][Full Text] [Related]
14. 18F-FDG/18F-FES standardized uptake value ratio determined using PET predicts prognosis in uterine sarcoma.
Yamamoto M; Tsujikawa T; Yamada S; Kurokawa T; Shinagawa A; Chino Y; Mori T; Kiyono Y; Okazawa H; Yoshida Y
Oncotarget; 2017 Apr; 8(14):22581-22589. PubMed ID: 28186981
[TBL] [Abstract][Full Text] [Related]
15. 18F-fluorodeoxyglucose positron emission tomography in uterine carcinosarcoma.
Ho KC; Lai CH; Wu TI; Ng KK; Yen TC; Lin G; Chang TC; Wang CC; Hsueh S; Huang HJ
Eur J Nucl Med Mol Imaging; 2008 Mar; 35(3):484-92. PubMed ID: 17952435
[TBL] [Abstract][Full Text] [Related]
16. Role of
Albano D; Zizioli V; Treglia G; Odicino F; Giubbini R; Bertagna F
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2019; 38(1):10-16. PubMed ID: 30396849
[TBL] [Abstract][Full Text] [Related]
17. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT
Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736
[TBL] [Abstract][Full Text] [Related]
18. Impact of (18) F-fluorodeoxyglucose (FDG)-positron-emission tomography/computed tomography (PET/CT) on management of patients with carcinoma invading bladder muscle.
Mertens LS; Fioole-Bruining A; Vegt E; Vogel WV; van Rhijn BW; Horenblas S
BJU Int; 2013 Oct; 112(6):729-34. PubMed ID: 23790129
[TBL] [Abstract][Full Text] [Related]
19. Is combined 18F-fluorodeoxyglucose-positron emission tomography/computed tomography superior to positron emission tomography or computed tomography alone for diagnosis, staging and restaging of pancreatic lesions?
Casneuf V; Delrue L; Kelles A; Van Damme N; Van Huysse J; Berrevoet F; De Vos M; Duyck P; Peeters M
Acta Gastroenterol Belg; 2007; 70(4):331-8. PubMed ID: 18330088
[TBL] [Abstract][Full Text] [Related]
20. Clinical impact of positron emission tomography (PET) with (18F)fluorodeoxyglucose (FDG) in head and neck tumours.
Ekberg T; Sörensen J; Engström M; Blomquist E; Sundin A; Anniko M
Acta Otolaryngol; 2007 Feb; 127(2):186-93. PubMed ID: 17364351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
